These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 844999)

  • 1. Bacillus Calmette-Guérin and dinitrochlorobenzene immunotherapy of chemically induced bladder tumors.
    Lamm DL; Harris SC; Gittes RF
    Invest Urol; 1977 Mar; 14(5):369-72. PubMed ID: 844999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor.
    Kadhim SA; Chin JL; Batislam E; Karlik SJ; Garcia B; Skamene E
    J Urol; 1997 Aug; 158(2):646-52. PubMed ID: 9224385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of intralesional and systemic BCG-application or a combined cyclophosphamide/BCG treatment on experimental bladder cancer.
    Adolphs HD; Thiele J; Kiel H
    Urol Res; 1979 Jun; 7(2):71-8. PubMed ID: 473445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant immunotherapy of N-[4(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced bladder tumors.
    Ibraheim EH; El Kappany H; Nigam VN; Brailovsky CA; Madarnas P; Elhilali MM
    Anticancer Res; 1984; 4(3):209-13. PubMed ID: 6465859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intralesional Bacillus Calmette-Guérin immunotherapy of canine venereal tumors.
    Hess AD; Catchatourian R; Zander AR; Epstein RB
    Cancer Res; 1977 Nov; 37(11):3990-4. PubMed ID: 143344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
    Yutkin V; Pode D; Pikarsky E; Mandelboim O
    J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of bacillus Calmette-Guérin-induced nitric oxide in bladder tumor cells may improve BCG treatment.
    Alvarez V; Lodillinsky C; Umerez S; Sandes E; Eiján AM
    Int J Mol Med; 2005 Oct; 16(4):565-71. PubMed ID: 16142388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative intralesional Bacillus Calmette-Guérin for mammary adenocarcinoma in rats.
    Lee YT
    Cancer Res; 1977 Oct; 37(10):3679-83. PubMed ID: 908015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of the intravesical MTP and BCG treatment of transplantable bladder cancer.
    Elhilali MM; Ibrahim EH; Nigam VN; Brailovsky CA; Madarnas P
    J Urol; 1983 Jun; 129(6):1265-9. PubMed ID: 6854814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of bladder cancer with intralesional injection with BCG.
    Calsini P; Scapicchi G; Gazzarini O; Melone F; Aulisi A; Pellegrini G; Fabris N; Provinciali M
    J Exp Pathol; 1987; 3(4):579-86. PubMed ID: 3454805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bacillus Calmette Guerin as adjuvant treatment for superficial bladder tumors using two different therapeutic schemes].
    Iturralde Codina A; Beyríe Tamayo W; Gozá León F; Muñoz YI
    Arch Esp Urol; 2004; 57(6):606-18. PubMed ID: 15382436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
    Demkow T; Alter A; Wiechno P
    Urol Int; 2008; 80(1):74-9. PubMed ID: 18204238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial.
    Pinsky CM; Camacho FJ; Kerr D; Geller NL; Klein FA; Herr HA; Whitmore WF; Oettgen HF
    Cancer Treat Rep; 1985 Jan; 69(1):47-53. PubMed ID: 3881177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
    Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
    J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of long-term chemotherapy and/or BCG on murine bladder cancer.
    Soloway MS
    Natl Cancer Inst Monogr; 1978 Dec; (49):327-32. PubMed ID: 748788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical bacillus Calmette-Guérin (BCG) in superficial bladder tumors. An overview.
    Debruyne FM; Witjes JA; vd Meijden AP
    Arch Esp Urol; 1990; 43 Suppl 2():133-8. PubMed ID: 2096774
    [No Abstract]   [Full Text] [Related]  

  • 20. [Intravesical immunotherapy of in situ carcinoma of the urinary bladder using Bacillus Calmette-Guerin (BCG)].
    Jakse G
    Wien Klin Wochenschr; 1987 Feb; 99(4):114-8. PubMed ID: 3577186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.